JiXing

JiXing is a leading biotechnology company committed to bringing innovative science and medicines to underserved patients in China.

We formed JiXing in early 2020, borne out of a two-year study of innovation, biotechnology, and access to healthcare in China. JiXing is a leading biotechnology company headquartered in Shanghai committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.

Founded
2020
Initial RTW investment
2020
Location
Shanghai, China
Phase
Clinical
Tags

Status

JiXing’s pipeline now includes 7 assets focused on cardiovascular and ophthalmology conditions with high unmet need through partnerships with Cytokinetics, Milestone, LENZ Therapeutics, and Oyster Pharma. RTW further capitalized JIXING by providing a Series B and C funding. 

Next catalyst

By working closely with the JiXing team we look to in-license additional late-clinical stage or commercial stage assets into its growing pipeline and provide further capital for business operation expansion.

Pipeline

Preclinical
Phase 1
Phase 2
Phase 3
Registrational
Commercial

  • OMECAMTIV MECABRIL: HFrEF

  • AFICAMTEN: oHCM

  • AFICAMTEN: nHCM

  • AFICAMTEN: HFpEF

  • ETRIPAMIL: PSVT

  • ETRIPAMIL: Attrial fibrilation (AFib)

  • OC-01: Dry eye disease

  • OC-02: Dry eye disease

  • LNZ100/101: Presbyopia

  • JX08: Demodex blepharitis

  • Pre-clinical
  • Phase 1-3
  • Registrational
  • Commercial

Key team members

Peter Fong, PhD

Peter Fong, PhD

Partner, President
Roderick Wong, MD

Roderick Wong, MD

Managing Partner, Chief Investment Officer
EXPLORE THE NEXT COMPANY
Rocket Pharmaceuticals Inc

Speak to a member of our team